Circa 2017
“Enabling early detection of diseases is one of the greatest opportunities we have for developing effective treatments,” Esfandyarpour said. “Maybe $1 in the U.S. doesn’t count that much, but somewhere in the developing world, it’s a lot of money.”
A two-part system
A combination of microfluidics, electronics and inkjet printing technology, the lab-on-a-chip is a two-part system: A clear silicone microfluidic chamber for housing cells sits on top of a reusable electronic strip.
Circa 2018 #artificialintelligence #doctor
Abstract: Online symptom checkers have significant potential to improve patient care, however their reliability and accuracy remain variable. We hypothesised that an artificial intelligence (AI) powered triage and diagnostic system would compare favourably with human doctors with respect to triage and diagnostic accuracy. We performed a prospective validation study of the accuracy and safety of an AI powered triage and diagnostic system. Identical cases were evaluated by both an AI system and human doctors. Differential diagnoses and triage outcomes were evaluated by an independent judge, who was blinded from knowing the source (AI system or human doctor) of the outcomes. Independently of these cases, vignettes from publicly available resources were also assessed to provide a benchmark to previous studies and the diagnostic component of the MRCGP exam. Overall we found that the Babylon AI powered Triage and Diagnostic System was able to identify the condition modelled by a clinical vignette with accuracy comparable to human doctors (in terms of precision and recall). In addition, we found that the triage advice recommended by the AI System was, on average, safer than that of human doctors, when compared to the ranges of acceptable triage provided by independent expert judges, with only a minimal reduction in appropriateness.
From: Yura Perov N [view email]
[v1] Wed, 27 Jun 2018 21:18:37 UTC (54 KB)
Biodiversity conservation, public health and improved livelihoods — dr gladys kalema-zikusoka, founder and CEO, conservation through public health.
Dr. Gladys Kalema-Zikusoka, is the Founder and CEO of Conservation Through Public Health (CTPH — https://ctph.org/), a 16-year old non-profit organization, based in Uganda, that promotes conservation by improving the quality of life of people and wildlife to enable them to coexist in and around protected areas in Africa, and she has become one of the leading conservationists and scientists working to save the critically endangered mountain gorillas of East Africa.
Dr. Kalema-Zikusoka is also on the Scientific Advisory Group for the Origins of Novel Pathogens (SAGO) of the World Health Organization (https://www.who.int/groups/scientific-advisory-group-on-the-…ago)/about)
Dr. Kalema-Zikusoka trained as a veterinarian at the University of London’s Royal Veterinary College. Between 1996 and 2000, she set up the first Veterinary Unit at the Uganda Wildlife Authority. From 2000 to 2003, she completed a zoological medicine residency and masters in specialized veterinary medicine at North Carolina State University and North Carolina Zoological Park.
Dr. Kalema-Zikusoka became an Ashoka Fellow in 2007 for merging Uganda’s wildlife management and rural public health programs to create common resources for both people and animals.
Bridging Technology And Medicine For The Modern Healthcare Ecosystem — Dr. Mona G. Flores, MD, Global Head of Medical AI, NVIDIA.
Dr. Mona Flores M.D., is the Global Head of Medical AI, at NVIDIA (https://blogs.nvidia.com/blog/author/monaflores/), the American multinational technology company, where she oversees the company’s AI initiatives in medicine and healthcare to bridge the chasm between technology and medicine.
Dr. Flores first joined NVIDIA in 2018 with a focus on developing their healthcare ecosystem. Before joining NVIDIA, she served as the chief medical officer of digital health company Human-Resolution Technologies after a 25+ year career in medicine and cardiothoracic surgery.
Dr. Flores received her medical degree from Oregon Health and Science University, followed by a general surgery residency at the University of California at San Diego, a Postdoctoral Fellowship at Stanford, and a cardiothoracic surgery residency and fellowship at Columbia University in New York.
Dr. Flores also has a Masters of Biology from San Jose State and an MBA from the University at Albany School of Business. She initially worked in investment banking for a few years before pursuing her passion for medicine and technology.
U.S. health officials on Wednesday reported the country’s first case of the Omicron variant of the coronavirus, in a person in California.
The Covid-19 case was identified by the California and San Francisco health departments in a person who had traveled to South Africa and returned on Nov. 22, the Centers for Disease Control and Prevention said in a release. The individual, who was fully vaccinated with the Moderna shot but had not received a booster, had mild symptoms and has since recovered, federal and local officials said. The person has been isolating since testing positive on Nov. 29. All close contacts have tested negative thus far.
The discovery of Omicron in the United States is not a surprise. Upon characterizing the mutations in the variant, scientists in South Africa last week quickly raised the world’s alarms about the potential threat it posed, but it had already started to circulate silently. Some two dozen countries, from the United Kingdom to Australia to Israel, have already reported cases, many in travelers.
Here’s a quick reminder that one of the expected results of the current pandemic is the slow, controlled, but inevitable destruction of the Canadian economy as government assets are secretly pulled out of circulation and redistributed to international bankers and their wealthiest clients.
Prime Minister Justin Trudeau’s Liberal government is asking Parliament to approve billions in new spending during a brief four-week sitting in Ottawa, but is facing questions because it has not released a full accounting of how it spent more than $600Bln last year.
Harrison.ai, a Sydney-based company that creates medical devices with AI technology, announced today it has raised $129 million AUD (about $92.3 million USD) in what it called one of the largest Series B rounds ever for an Australian startup.
The funding was led by returning investor Horizons Ventures and included participation from new investors Sonic Healthcare and I-MED Radiology Network. Existing backers Blackbird Ventures and Skip Capital also returned for the round, which brings Harrison.ai’s total raised over the past two years to $158 million AUD.
Harrison.ai announced it has also formed a joint venture with Sonic Healthcare, one of the world’s largest medical diagnostics providers, to develop and commercialize new clinical AI solutions in pathology. The partnership will focus first on histopathology, or the diagnosis of tissue diseases.
The market introduction of the MR-Linac technology improves the patient care via the real-time imaging of the targeted PTVs. Conventional Water Phantoms with ferromagnetic material become prohibited due to safety reasons. To overcome this situation, LAP introduced the MR-compatible Water Phantom THALES 3D MR SCANNER. Dr Thierry Gevaert, medical physicist and co-ordinator at the UZ Brussel institute, will share his experience with the THALES 3D MR SCANNER during the commissioning of the MRIdian Linac of Viewray. Furthermore, he will highlight which benefits played an important role for his clinical workflow.
During the webinar you will also learn more about the THALES technology for commissioning and quality-assurance processes of conventional Linacs.